Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring

By LabMedica International staff writers
Posted on 28 Jul 2015
At AACC 2015 (July 26-30; Atlanta, GA, USA) research teams presented results of successful testing of two new potential methods for diagnosing and monitoring diabetes in its standard or gestational forms. The findings may lead to easier, timelier, and more affordable ways of identifying and treating this chronic disease.

One test study, by a research team led by Prof. Sridevi Devaraj, PhD, of Texas Children’s Hospital and Baylor College of Medicine (Houston, TX, USA), was to determine if a blood biomarker could be identified for gestational diabetes (GD), which occurs only during pregnancy and poses serious health risks for both mother and baby.

Today’s test for standard diabetes, which measures levels of the biomarker glycated hemoglobin (HbA1c), has limited usefulness for GD. The HbA1c test measures patient average glucose blood levels over a period of 3 months, and cannot be used to determine a patient’s blood glucose values on a daily, or even weekly, basis. This makes it challenging to closely track glucose levels during relatively few weeks of pregnancy, especially as GD is not diagnosed until the 3rd trimester.

Using stored blood samples collected from 124 pregnant women, Prof. Devaraj and her colleagues measured the levels of 3 types of proteins. They found that the levels of one—1,5Anhydroglucitol (1,5AG)—were significantly different in the women diagnosed with GD. The researchers were also able to establish a specific cutoff level at which the concentration of 1,5AG became a reliable predictor of which women had diabetes. One of the main potential advantages of 1,5AG as a biomarker for GD is its short “halflife” of 2 weeks, compared to HbA1c’s of 3 months.

“Our findings are very preliminary and need to be confirmed in larger groups of women,” said Prof. Devaraj, “but, if confirmed, they suggest a possible new and more immediate approach for diagnosing and monitoring diabetes during pregnancy.”

For the second test study, a research team led by Joris R. Delanghe, MD, PhD, Ghent University (Ghent, Belgium), investigated the novel view of whether fingernail clippings could be used instead of blood to diagnose and monitor diabetes. They collected nail clippings from 25 people with and 25 without diabetes. After the clippings were ground into powder, a relatively inexpensive spectrometer was used to measure the amount of nail protein that had undergone glycation (bonding with sugar molecules).

“We found a striking difference in the measurements between the control group and the patients with diabetes,” said Prof. Delanghe, “This finding suggests that nail clippings may serve as a reliable and noninvasive diagnostic tool,” with potential to make diagnosing diabetes much simpler and less expensive. Nail clippings, unlike blood samples, can be obtained noninvasively. They also take up little space and can be stored at room temperature for at least 1 month without affecting spectrometer outcomes.

“The proposed test may become particularly useful in low and middle income countries, where laboratories are often located long distances from where patients live,” said Prof. Delanghe.

Related Links:

American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.